MediSieve’s Magnetic Blood Filtration System is an extracorporeal therapy which uses antibody coated magnetic beads to specifically target and remove harmful substances from the bloodstream. It is a novel, platform therapy which could be a life-saving intervention multiple diseases and conditions (watch video). The company’s first product is for the removal of IL-6, a key inflammatory cytokine that play a major role in sepsis, COVID-19, cytokine storms (including CRS) and other diseases of hyperinflammation. The technology has been validated in pre-clinical testing, and MediSieve is now raising £3.7M to support a pivotal clinical trial, having already secured a £1.6M grant from UKRI. The market, worth £9.2B in the EU and US, will be reached in 2023.
MediSieve is a multi-award-winning spinout from University College London. Since its foundation in 2015, it has secured over £2.1M of equity investment and £4M of grants from funders including the Wellcome Trust, Innovate UK, EU Commission and UKRI. The company has two patents granted in the US and pending worldwide, and all IP is fully owned by MediSieve. There are 12 full-time members of staff, including 5 PhDs, supported by a strong team of advisors and consultants with decades of regulatory, commercial and clinical experience, including global sepsis KoLs.
In benchtop studies, MediSieve’s approach has been shown to reduce clinically relevant IL-6 levels by 90% in 5 minutes from 120ml human plasma. A similar reduction is expected from a patient in approximately 3 hours, providing doctors with a potentially life-saving intervention for patients with hyperinflammation.
MediSieve is looking to raise £3.7M from experienced investors who wish to join us on our journey. If you are interested in participating in this round, please contact CEO George Frodsham (email@example.com; +44 (0)7576 948 494).